quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:00:00·66d
PRRelease
OS Therapies Incorporated logo

OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma

OSTX· OS Therapies Incorporated
Health Care
Original source

Companies

  • OSTX
    OS Therapies Incorporated
    Health Care

Recent analyst ratings

  • Apr 2UpdateLake Street$19.00

Related

  • PR8d
    OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes
  • PR11d
    OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor
  • PR15d
    OS Therapies Appoints Craig Eagle, MD as Strategic Advisor
  • SEC21d
    OS Therapies Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
  • PR21d
    OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors
  • SEC21d
    SEC Form 424B5 filed by OS Therapies Incorporated
  • SEC23d
    OS Therapies Incorporated filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • SEC23d
    SEC Form 424B7 filed by OS Therapies Incorporated
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022